Neuren Pharmaceuticals Limited (NURPF)
| Market Cap | 1.87B +10.3% |
| Revenue (ttm) | 48.10M -68.2% |
| Net Income | 14.01M -86.4% |
| EPS | 0.11 -86.4% |
| Shares Out | n/a |
| PE Ratio | 133.60 |
| Forward PE | 47.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 16.10 |
| Previous Close | 16.01 |
| Day's Range | 16.10 - 16.10 |
| 52-Week Range | 7.70 - 17.25 |
| Beta | 1.59 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo... [Read more]
Financial Performance
In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.
Financial numbers in AUD Financial StatementsNews
Neuren Pharmaceuticals Earnings Call Transcript: H1 2026
Robust cash reserves and strong DAYBUE royalty income enabled a new dividend program, while European approval and U.S. sales momentum drive growth. NNZ-2591's phase III KOALA trial is progressing well, with multiple regulatory and commercial catalysts ahead.
Neuren Pharmaceuticals Quarterly report: H1 2026
Neuren Pharmaceuticals has published its H1 2026 quarterly earnings report on August 25, 2026.
Neuren Pharmaceuticals Earnings release: H1 2026
Neuren Pharmaceuticals released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
Neuren Pharmaceuticals Slides: H1 2026
Neuren Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Neuren Pharmaceuticals Transcript: AGM 2026
Strong financial growth driven by DAYBUE royalties and expanding U.S. market presence was highlighted, with strategic focus on advancing NNZ-2591 clinical trials and exploring new indications. Dividend policy and capital management remain under review, while regulatory and market challenges were openly discussed.
Neuren Pharmaceuticals Annual report: H2 2025
Neuren Pharmaceuticals has published its H2 2025 annual report on February 27, 2026.
Neuren Pharmaceuticals Earnings release: H2 2025
Neuren Pharmaceuticals released its H2 2025 earnings on February 27, 2026, summarizing the period's financial results.
Neuren Pharmaceuticals Transcript: Investor update
A new share buyback of up to 5% was approved, reflecting strong financials and confidence in future growth. Key clinical programs for PMS, Pitt Hopkins, and HIE are prioritized, with PMS phase III now underway and additional studies targeted for late 2024. Management remains focused on orphan indications and sees recent share price volatility as disconnected from fundamentals.
Neuren Pharmaceuticals Press release: Investor update
Neuren Pharmaceuticals issued a press release on February 11, 2026, disclosing material business information to investors.
Neuren Pharmaceuticals Slides: Investor Presentation
Neuren Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 9, 2025.
Neuren Pharmaceuticals upgraded to Buy from Hold at Jefferies
Jefferies analyst David Stanton upgraded Neuren Pharmaceuticals to Buy from Hold with a price target of A$16.75, up from A$11.20. Acadia acquired ex-North American rights to trofinetide and global rig...